2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. ADC Payload

ADC Cytotoxin

ADC Payload

Related Products

PDF 0.5 MB

ADC payloads are cytotoxic agents that induce target cell death in Antibody Drug Conjugates (ADCs). An ADC is a targeted agent composed with a monoclonal antibody, a linker and a payload. The payload is the most important component as it determines the potency to kill cancer cells of an ADC.

There are many payloads which are currently being used such as Calicheamicins, Duocarmycins, Pyrrolobenzodiazepines (PBDs), Camptothecins, Daunorubicins/Doxorubicins, Auristatins and Maytansinoids. They can be divided in two classes based on their mechanism of action, DNA damaging agents and tubulin inhibitors. Among them Calicheamicins, Duocarmycins and PBDs are DNA minor grove binders, Camptothecins and Daunorubicins/Doxorubicins are topoisomerase inhibitors, which are DNA damaging agents. Auristatins and Maytansinoids are tubulin inhibitors.

ADC Payload Isoform Specific Products:

ADC Payload Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-48878
    Exatecan analog 36
    		98.71%
    Exatecan analog 36 is a analog of Exatecan (HY-13631). Exatecan (DX-8951) is a common toxin component in ADC preparation (ADC Cytotoxin) and an inhibitor of DNA topoisomerase I (IC50=2.2 μM).
    Exatecan analog 36
  • HY-402091
    SJG-136 intermediate-1
    		99.95%
    SJG-136 intermediate-1 (compound 19) is an intermediate for synthesizing SJG-136. SJG-136 is a DNA cross-linking agent, with an XL50 of 45 nM for pBR322 DNA.
    SJG-136 intermediate-1
  • HY-79255
    Fmoc-MMAF-OMe
    		98.58%
    Fmoc-MMAF-OMe is an anticancer agent and tubulin polymerization inhibitor with an Fmoc protecting group. The active ingredient of Fmoc-MMAF-OMe, MMAF (HY-15579), is the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs).
    Fmoc-MMAF-OMe
  • HY-15142A
    Doxorubicin
    Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy.
    Doxorubicin
  • HY-112898
    DC1SMe
    		98.0%
    DC1Sme, a DC1 derivative, exhibits IC50 values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.
    DC1SMe
  • HY-130978
    Duocarmycin DM
    		99.15%
    Duocarmycin DM, a DNA minor-groove alkylator, is an antibody agent conjugates (ADCs) toxin. Duocarmycin DM is based on its characteristic curved indole structure and a spirocyclopropylcyclohexadienone electrophile to act anticancer activity.
    Duocarmycin DM
  • HY-B0015S1
    Paclitaxel-d5 (benzoyloxy)
    		98.12%
    Paclitaxel-d5 (benzoyloxy) is the deuterium labeled Paclitaxel. Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.
    Paclitaxel-d<sub>5</sub> (benzoyloxy)
  • HY-129355
    Duocarmycin analog-1
    Duocarmycin analog-1 is an analog of Duocarmycin, and used as an DNA alkylator and ADC cytotoxin.
    Duocarmycin analog-1
  • HY-16560S
    Camptothecin-d5
    		99.61%
    Camptothecin-d5 is the deuterium labeled Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells.
    Camptothecin-d<sub>5</sub>
  • HY-160179
    Glucocorticoid receptor agonist-4
    		99.80%
    Glucocorticoid receptor agonist-4 (Compound Preparation 5) is a glucocorticoid receptor agonist that can be conjugated to TNF-α antibodies for the study of autoimmune and inflammatory diseases.
    Glucocorticoid receptor agonist-4
  • HY-160097
    AXC-666
    		99.75%
    AXC-666, an immune agonist, is a Imiquimod (HY-B0180) derivative.
    AXC-666
  • HY-132164
    Gly-7-MAD-MDCPT
    Gly-7-MAD-MDCPT (compound 4b) is an anticancer agent. Gly-7-MAD-MDCPT is a Camptothecin (HY-16560) compound, it shows cytotoxicity to various cancer cells with IC50 values of 10-1000 nM.
    Gly-7-MAD-MDCPT
  • HY-160177
    Glucocorticoid receptor agonist-3
    		98.46%
    Glucocorticoid receptor agonist-3 (Preparation 6) is a glucocorticoid receptor agonist.
    Glucocorticoid receptor agonist-3
  • HY-100503
    Maytansinoid DM4
    Maytansinoid DM4 is a thiol-containing maytansine derivative with highly potent cytotoxicity. Maytansinoid DM4 can be used as a cytotoxic moiety of ADC.
    Maytansinoid DM4
  • HY-77572
    7-Epi 10-desacetyl paclitaxel
    		99.76%
    7-Epi 10-desacetyl paclitaxel (7-epi-10-deacetyltaxol), a taxol derivative, exhibits cytotoxicity against HeLa cells with an IC50 of 85 μM.
    7-Epi 10-desacetyl paclitaxel
  • HY-W1124025
    (5-Cl)-DXd
    (5-Cl)-DXd, a derivative of DXd (HY-13631), is a cytotoxic drug that can be used in synthesis of CDH3-targeting antibody-drug conjugates (ADCs).
    (5-Cl)-DXd
  • HY-175615
    RSL3-NH2
    RSL3-NH2 is a GPX4 inhibitor and ferroptosis inducer. RSL3-NH2 triggers the iron-dependent cell death pathway associated with lipid peroxidation by inhibiting GPX4 activity. RSL3-NH2 exhibits significant cytotoxicity against colorectal cancer cells and effectively induces their ferroptosis. RSL3-NH2 can serve as a ADC payload for synthesizing antibody-drug conjugates (ADC) and be used in colorectal cancer-related research.
    RSL3-NH2
  • HY-176844
    eIF4A-IN-1 intermediate
    eIF4A-IN-1 intermediate (Compound 71E) is an intermediate of Eukaryotic translation initiation factor 4A (eIF4A) inhibitor. eIF4A-IN-1 intermediate can be used as a cytotoxic payload for synthesis of antibody-drug conjugates (ADCs).
    eIF4A-IN-1 intermediate
  • HY-160806
    (5-Cl)-Exatecan
    (5-Cl)-Exatecan is a derivative of Exatecan (HY-13631) and a DNA topoisomerase inhibitor. (5-Cl)-Exatecan serves as the cytotoxic payload component in antibody-drug conjugates (ADC) targeting ROR1-positive cancers. (5-Cl)-Exatecan is applicable for the research of ROR1-positive cancers.
    (5-Cl)-Exatecan
  • HY-133571
    Aminohexylgeldanamycin
    		99.56%
    Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent HSP90 inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities.
    Aminohexylgeldanamycin
Cat. No. Product Name / Synonyms Application Reactivity
ADC Payload Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.